(Q36611916)

15 August 2017

Exploring two two-edged swords (English)

1 reference

15 August 2017

David J Brenner

1

1 reference

15 August 2017

27 June 2012

1 reference

15 August 2017

1 reference

15 August 2017

178

1 reference

15 August 2017

1

1 reference

15 August 2017

7-16

1 reference

Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS).

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Emerging technologies in proton therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The RABiT: a rapid automated biodosimetry tool for radiological triage. II. Technological developments

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Hyperfractionated or accelerated radiotherapy for head and neck cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Taking a new biomarker into routine use--a perspective from the routine clinical biochemistry laboratory

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Secondary neutrons in clinical proton radiotherapy: a charged issue

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Should randomized clinical trials be required for proton radiotherapy?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

THE RESULTS AND METHODS OF TREATMENT OF CANCER BY RADIATION

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Solid tumor risks after high doses of ionizing radiation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Radiation-induced second cancers: the impact of 3D-CRT and IMRT

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The price of innovation: new estimates of drug development costs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

HUman MicroNucleus project: international database comparison for results with the cytokinesis-block micronucleus assay in human lymphocytes: I. Effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Optimizing the time course of brachytherapy and other accelerated radiotherapeutic protocols

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Invited review: intrinsic radiosensitivity as a predictor of patient response to radiotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Accelerated fractionation vs hyperfractionation: rationales for several treatments per day.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Dose fractionation, dose rate and iso-effect relationships for normal tissue responses.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The design of clinical trials comparing pi-meson therapy with conventional radiotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The los alamos scientific laboratory ion linear accelerator program

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

The RABIT: a rapid automated biodosimetry tool for radiological triage

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Longevity of atomic-bomb survivors.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Is Proton Beam Therapy Cost Effective in the Treatment of Adenocarcinoma of the Prostate?

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573181

Optimum fractionation for high-dose-rate endoesophageal brachytherapy following external irradiation of early stage esophageal cancer

21 October 2018

1 reference

12 December 2020

Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer

1 reference

12 December 2020

Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer

1 reference

12 December 2020

Tumor response to radiotherapy regulated by endothelial cell apoptosis

1 reference

12 December 2020

Accelerated hyperfractionated irradiation for advanced head and neck cancer: effect of shortening the median treatment duration by 13 days

1 reference

12 December 2020

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

12 December 2020

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

1 reference

12 December 2020

Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial

1 reference

12 December 2020

Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses

1 reference

12 December 2020

The Possibility of Therapeutic Applications of Beams of Negative π-Mesons

1 reference

12 December 2020

What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy

1 reference

12 December 2020

Sources of variability in the human lymphocyte micronucleus assay: A population‐based study

1 reference

12 December 2020

An interpretation of some biological results obtained in range-modulated negative pion beams

1 reference

12 December 2020

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

1 reference

12 December 2020

Observational cosmology. VI. The microwave background and the Sachs-Wolfe effect

1 reference

12 December 2020

Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships

1 reference

12 December 2020

Dangers of the clinical use of the NSD formula for small fraction numbers

1 reference

12 December 2020

Identifiers

DOI

10.1667/RR3085.1

1 reference

15 August 2017

1 reference

PMC publication ID

3573181

15 August 2017

PubMed publication ID

22738761

1 reference

PMC publication ID

3573181